By Ellen ‘t Hoen The movement to delink the cost of developing medicines from their market price received another boost this week, with the publication of a new report from the Netherlands Council for Public Health and Society, an official government advisory body. This report is part of a recent phenomenon in which even the Read more about Growing consensus on importance of delinkage in pharmaceutical R&D[…]